Tonix Pharmaceuticals Holding Corp. (TNXP)
13.14
-0.23
(-1.72%)
USD |
NASDAQ |
Sep 04, 16:00
13.33
+0.19
(+1.45%)
After-Hours: 20:00
Tonix Pharmaceuticals Enterprise Value : 45.69M for Sept. 4, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 04, 2026 | 45.69M |
| September 03, 2026 | 49.55M |
| September 02, 2026 | 49.72M |
| September 01, 2026 | 59.80M |
| August 31, 2026 | 61.81M |
| August 28, 2026 | 53.25M |
| August 27, 2026 | 52.74M |
| August 26, 2026 | 54.09M |
| August 25, 2026 | 54.42M |
| August 24, 2026 | 34.10M |
| August 21, 2026 | 35.78M |
| August 20, 2026 | 33.10M |
| August 19, 2026 | 38.81M |
| August 18, 2026 | 37.63M |
| August 17, 2026 | 37.63M |
| August 14, 2026 | 38.47M |
| August 13, 2026 | 34.94M |
| August 12, 2026 | 26.04M |
| August 11, 2026 | 32.26M |
| August 10, 2026 | 36.46M |
| August 07, 2026 | 27.05M |
| August 06, 2026 | 20.67M |
| August 05, 2026 | 14.12M |
| August 04, 2026 | 13.28M |
| August 03, 2026 | 4.130M |
| Date | Value |
|---|---|
| July 31, 2026 | -6.869M |
| July 30, 2026 | -5.526M |
| July 29, 2026 | -15.27M |
| July 28, 2026 | -8.044M |
| July 27, 2026 | -0.8238M |
| July 24, 2026 | -9.052M |
| July 23, 2026 | 3.374M |
| July 22, 2026 | 2.870M |
| July 21, 2026 | 19.16M |
| July 20, 2026 | 9.420M |
| July 17, 2026 | 33.77M |
| July 16, 2026 | 24.03M |
| July 15, 2026 | 20.00M |
| July 14, 2026 | 10.76M |
| July 13, 2026 | 21.59M |
| July 10, 2026 | 35.45M |
| July 09, 2026 | 43.84M |
| July 08, 2026 | 39.65M |
| July 07, 2026 | 38.47M |
| July 06, 2026 | 38.47M |
| July 02, 2026 | 32.26M |
| July 01, 2026 | 33.94M |
| June 30, 2026 | 39.31M |
| June 29, 2026 | -3.061M |
| June 26, 2026 | 3.615M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Exelixis, Inc. | 14.01B |
| Inovio Pharmaceuticals, Inc. | 89.08M |
| Heron Therapeutics, Inc. | 171.90M |
| ACADIA Pharmaceuticals, Inc. | 3.941B |
| Alnylam Pharmaceuticals, Inc. | 35.27B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.55M |
| Revenue (Quarterly) | 13.54M |
| Total Expenses (Quarterly) | 54.10M |
| EPS Diluted (Quarterly) | -2.438 |
| Gross Profit Margin (Quarterly) | 90.24% |
| Profit Margin (Quarterly) | -299.4% |
| Earnings Yield | -98.43% |
| Normalized Earnings Yield | -98.43 |